Conference
A Phase I Trial of Two Sequence-Specific Schedules of Decitabine and Vorinostat in Patients with Acute Myeloid Leukemia (AML).
Abstract
Abstract
Background: Epigenetic silencing of genes has been documented in AML. This phase I trial evaluates the safety, tolerability, and maximum tolerated dose (MTD) of two schedules of administration of the hypomethylating agent decitabine in combination with the pan-selective histone deacetylase inhibitor vorinostat.
Authors
Yee KWL; Minden MD; Brandwein J; Schimmer A; Schuh A; Gupta V; Messner HA; Foley R; Wasi P; Zwiebel JA
Volume
110
Publisher
American Society of Hematology
Publication Date
November 16, 2007
DOI
10.1182/blood.v110.11.908.908
Conference proceedings
Blood
Issue
11
ISSN
0006-4971